World Sleep Industry ENCYCLOPEDIA

Narcolepsy Patient Follow-Up Systems

4.1.3

Definition, population, and system boundary

A narcolepsy patient follow-up system is a combination of software and services that continuously organizes symptoms, treatment, safety, function, comorbidity, and life-stage management for people whose specialist diagnosis has already been established. It connects patients, caregivers, sleep or neurology specialists, primary care, and school or occupational support, but it does not diagnose narcolepsy from phone behavior, a sleepiness scale, wearables, or a camera. PSG, MSLT, and cerebrospinal fluid orexin findings may be imported as clinical records; the follow-up platform must not reinterpret one test and change the diagnosis. Nor should it automatically relabel ordinary fatigue, insufficient sleep, or another cause of sleepiness as narcolepsy.

The system should identify narcolepsy type 1 or type 2, eligible ages, diagnosing organization, treatment team, coverage hours, and an emergency alternative. The symptom combinations differ between types, and not every patient has cataplexy. The platform is also not an ordinary medication reminder, continuous vital-sign monitor, crisis line, licensing authority, or surveillance tool for a school or employer. Asynchronous uploads must disclose their delay and who is responsible for review.

Symptom, event, and functional profile

Follow-up should represent irresistible sleepiness or sleep episodes, planned naps, cataplexy, sleep paralysis, hypnagogic or hypnopompic hallucinations, disrupted nighttime sleep, nightmares, automatic behavior, attention, and memory as separate dimensions. Sleepiness is difficulty staying awake, whereas fatigue can be a lack of energy; they may coexist but are not interchangeable. One composite score can hide divergent symptoms. Every scale needs its name, version, language, recall period, respondent, and clinical interpretation preserved. It supports trending and communication rather than independently proving adequate treatment or activity safety.

A cataplexy record may include estimated time, emotional trigger, body area affected, whether consciousness was retained, duration, fall or injury, witness description, and recovery. Unwitnessed episodes, retrospective entries, and caregiver reports need explicit provenance. Sudden weakness may also arise from syncope, seizure, medication, or another cause, so the system should not classify it automatically. A patient may be unable to enter information during an event; later entry, voice input, short quick fields, and optional caregiver assistance are therefore useful. The goal is a pattern that can inform a discussion, not second-by-second completeness for every episode.

Treatment implementation and medication safety

Management may combine a regular schedule, planned naps, risk reduction, psychological and social support, and medication targeted to daytime sleepiness, cataplexy, or nighttime sleep. The system should use a confirmed prescription as its source and record generic name, formulation, target symptom, dose and timing, prescriber, actual use, reason for missed use, perceived benefit, and adverse effects. Starting, increasing, tapering, stopping, switching, or replacing a missed dose must originate from an authorized clinical decision; a daily score, missed dose, or event count must not drive an autonomous change.

Monitoring requirements differ by medicine. Wake-promoting agents or stimulants may involve blood pressure, heart rate, appetite, anxiety, insomnia, psychiatric effects, and misuse. Particular drugs may require attention to serious rash, liver or kidney function, QT interval, reproductive plans, or interactions. Oxybate products also involve central and respiratory depression, alcohol and other sedatives, misuse or diversion, and product-specific safety programs. Tasks should be generated from the confirmed prescription and current local labeling rather than a universal checklist. Worsening breathing, severe rash, syncope, major psychiatric or behavioral change, suspected overdose, or misuse requires a defined human or emergency route.

Everyday safety and hazardous activities

Driving, cycling, swimming or bathing alone, working at height, open flame, cooking, machinery, night work, and care of children require a written plan developed by the patient and clinical team. The plan may address early signs of sleepiness, breaks, avoiding solitary exposure, an informed companion, alternative transport, and review after an event, but a general recommendation is not a permanent clearance. A near miss, collision, unheralded sleep episode, injury during cataplexy, or treatment change should prompt reassessment.

Driving rules differ by jurisdiction, license class, and occupation, so the system should present an authoritative local source and its update date. A subjective sleepiness score, wearable “alertness” score, MWT, or reaction-time result cannot alone prove fitness to drive. Improvement on one test still needs the history, symptom control, medication response, incident record, and professional judgment. The platform must not issue fitness certificates automatically or infer dangerous driving from geofencing. If a person reports inability to stay awake, the immediate pathway should clearly prioritize stopping hazardous activity and contacting an appropriate local professional service.

Comorbidity, life stage, and social support

Long-term follow-up should consider obstructive sleep apnea, weight and metabolic change, depression and anxiety, attention problems, unusual nighttime behavior, and the effects of other illnesses or medicines on sleepiness. A positive mood questionnaire is not a psychiatric diagnosis, and group comorbidity rates do not predict an individual. Self-harm or suicidal thoughts, psychosis, marked agitation, or inability to remain safe needs an appropriate local crisis or emergency assessment. Pregnancy planning, pregnancy, breastfeeding, surgery, a new diagnosis, or a new medicine should trigger complete medication review rather than autonomous discontinuation by the platform.

Children and adolescents need age-appropriate language and measures, with the young person’s, parent’s, and teacher’s observations stored separately because they can be complementary or conflicting. School support may include a place for planned naps, examination or schedule adjustments, travel, and sports safety, but disclosure should remain under the control of the patient and legally authorized person. Transition to adult care should progressively transfer self-management and hand over diagnostic evidence, symptom course, effective and ineffective treatment, adverse effects, safety planning, and accommodations. The individual’s authorization must be re-established rather than extending a guardian account indefinitely.

Workflow, data, and governance

Every task needs an owner, due time, backup person, and evidence of closure. Worsening sleepiness, increased cataplexy, injury, serious adverse drug effects, hazardous activity, and a mental health crisis need different tiers so that large volumes of low-value alerts do not obscure a critical event. Physicians, pharmacists, nurses, coordinators, customer support, and school contacts should see only what their work requires. General customer support cannot manage a crisis, decide whether an event is cataplexy, or change a prescription. When care transfers between organizations or the patient travels, is hospitalized, or loses medication supply, unfinished tasks and the currently accountable team must remain visible.

The combination of symptoms, mental health, controlled medication, location, driving, school, and occupational data is highly sensitive. The service should use data minimization, granular authorization, least privilege, strong authentication, protection in transit and at rest, audit, backup, account unlinking, and retention limits. Treatment, research, model training, payment, and workplace disclosure require separate purposes and permissions. Wearables and models trained on rare events have limited samples; version, intended population, false positives, and missed detections need disclosure and human review. No entry may mean no event, forgotten entry, inability to report, or technical failure, so it cannot automatically become zero events or noncooperation.

Evidence, evaluation, and procurement

Guidelines support symptom-specific pharmacologic and nonpharmacologic options and emphasize differences between adults and children, daytime sleepiness and cataplexy, comorbidities, tolerability, and interactions. They provide a basis for follow-up content but do not prove that any particular platform improves outcomes. Rare-disease studies are often small, while validity, responsiveness, and patient-centered minimal important change remain limited for several patient-reported measures. Planned naps, school support, and individual safety plans have a practical role in comprehensive care, but they cannot be marketed as a cure or a guarantee against accidents.

Evaluation should jointly report symptom-specific trends, patient goals, daytime function and quality of life, feasibility of planned naps, injuries and near misses, medication benefit and adverse effects, completion of vital-sign or test tasks, comorbidity referral, follow-up timeliness, school or work support, completeness of transition to adult care, distinct reasons for loss to follow-up, alert burden, and staff time. App activity, reminder clicks, a single ESS, or episode count does not independently represent disease control. Procurement should examine clinical ownership, prescription and label updates, age and regional configuration, human capacity, algorithm evidence, privacy and security, interoperability, and downtime procedures. Deployment should be staged and reversible, with safer and more sustainable daily life—not maximal monitoring—as the goal.